Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Takara Bio Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Takara Bio şirketinin toplam hissedar öz sermayesi ¥111.5B ve toplam borcu ¥0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla ¥121.8B ve ¥10.2B dir. Takara Bio 'in FAVÖK'ü ¥873.0M faiz karşılama oranı -4.5 dur. Şirketin ¥38.0B tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

Borç/özkaynak oranı

JP¥0

Borç

Faiz karşılama oranı	-4.5x
Nakit	JP¥37.97b
Eşitlik	JP¥111.51b
Toplam yükümlülükler	JP¥10.24b
Toplam varlıklar	JP¥121.75b

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 4974 'nin kısa vadeli varlıkları ( ¥61.0B ) kısa vadeli yükümlülüklerini ( ¥7.8B ) aşıyor.

Uzun Vadeli Yükümlülükler: 4974 şirketinin kısa vadeli varlıkları ( ¥61.0B ) uzun vadeli yükümlülüklerini ( ¥2.4B ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 4974 borçsuzdur.

Borcun Azaltılması: 4974 un 5 yıl önce borcu yoktu.

Borç Kapsamı: 4974 un borcu yoktur, dolayısıyla işletme nakit akışı tarafından karşılanmasına gerek yoktur.

Faiz Kapsamı: 4974 şirketinin borcu bulunmadığından faiz ödemelerinin karşılanması söz konusu değildir.

Takara Bio Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Takara Bio Inc. to Report Q2, 2025 Results on Nov 08, 2024

First quarter 2025 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorates as stock falls 17%

Takara Bio Inc. to Report Q1, 2025 Results on Aug 08, 2024

Full year 2024 earnings: EPS and revenues miss analyst expectations

Takara Bio Inc., Annual General Meeting, Jun 21, 2024

Consensus EPS estimates fall by 30%

Takara Bio Inc. Proposes Dividend for the Fiscal Year Ending March 31, 2024, Effective June 24, 2024

Consensus EPS estimates fall by 56%

Price target decreased by 17% to JP¥1,600

Upcoming dividend of JP¥17.00 per share

Takara Bio Inc.(TSE:4974) dropped from FTSE All-World Index (USD)

Takara Bio Inc. to Report Fiscal Year 2024 Results on May 10, 2024

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates increase by 29%, revenue downgraded

Takara Bio Inc. to Report Q3, 2024 Results on Feb 14, 2024

Consensus EPS estimates fall by 15%

Price target decreased by 17% to JP¥1,933

Takara Bio Inc. Revises Consolidated Earnings Guidance for the Year Ending March 31, 2024

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Now 20% undervalued after recent price drop

Takara Bio Inc. to Report Q2, 2024 Results on Nov 09, 2023

Takara Bio Inc. to Report Q2, 2024 Results on Nov 14, 2023

Now 20% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 16%

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Takara Bio Inc. to Report Q1, 2024 Results on Aug 08, 2023

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Takara Bio Inc., Annual General Meeting, Jun 23, 2023

Upcoming dividend of JP¥42.00 per share at 2.3% yield

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Takara Bio Inc. Provides Dividend Guidance for the Fiscal Year Ending Mar. 31, 2023

Takara Bio Inc. to Report Q3, 2023 Results on Feb 09, 2023

Price target decreased to JP¥2,250

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Takara Bio Inc. Provides Dividend Guidance for the Fiscal Year Ending Mar. 31, 2023

Takara Bio Inc. to Report Q2, 2023 Results on Nov 10, 2022

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to JP¥2,400

Takara Bio Inc. to Report Q1, 2023 Results on Aug 04, 2022

Price target decreased to JP¥2,515

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Takara Bio Inc., Annual General Meeting, Jun 24, 2022

Less than half of directors are independent

Takara Bio Inc. to Report Fiscal Year 2022 Results on May 12, 2022

Upcoming dividend of JP¥30.00 per share

Consensus revenue estimates increase by 16%

Price target decreased to JP¥2,742

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased to JP¥2,792

Price target decreased to JP¥3,012

Second quarter 2022 earnings released: EPS JP¥33.09 (vs JP¥15.53 in 2Q 2021)

Consensus EPS estimates increase to JP¥91.00

First quarter 2022 earnings released: EPS JP¥50.04 (vs JP¥3.36 in 1Q 2021)

Takara Bio Inc. Provides Earnings Guidance for the Six Months Ending September 30, 2021; Provides Earnings Guidance for the Year Ending March 31, 2022

Full year 2021 earnings released: EPS JP¥79.28 (vs JP¥31.72 in FY 2020)

Upcoming dividend of JP¥14.00 per share

Takara Bio Inc. to Report Fiscal Year 2021 Results on May 13, 2021

Analysts increase EPS estimates to JP¥53.65

Third quarter 2021 earnings released: EPS JP¥28.67 (vs JP¥5.26 in 3Q 2020)

New 90-day high: JP¥3,045

New 90-day low: JP¥2,752

Takara Bio Inc. to Report Q3, 2021 Results on Feb 10, 2021

New 90-day high: JP¥3,020

Takara Bio Inc. to Report Q2, 2021 Results on Nov 10, 2020

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin